SLAM BioTherapeutics
June 17, 2025
Company Presentation
Oncology
153A
SLAM Bio is an oncology biotech company developing a platform of first-in-class antibodies and ADCs against signaling lymphocytic activation molecule (SLAM) protein family. This is an intriguing biotech investment opportunity, one that holds potential to significantly impact the lives of patients with life threatening cancers, including AML, MDS, and CTCL. We will be in the clinic early 2026. SLAM’s lead program targets CD84 (SLAMF5), a cell surface adhesion molecule that is expressed on a spectrum of blood cancers and on immune suppressor cells in the micro-environment of all cancers. We have pre-clinical in vivo data in AML, MDS, CTCL. We have raised over $10M to date. We are initiating a $30 million Series A in Q2 2025. Guiding our biotech is a seasoned and proven oncology leadership team with a track record of high multiple exits.
Company HQ City:
Thousand Oaks
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2022
Lead Product in Development:
ADC for AML, MDS and CTCL
CEO
Rick Heinick
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
Filing IND
What is your next catalyst (value inflection) update?
4th Quarter 2025
Website
www.slambio.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}